Edgewise CMO granted 65K options at $43.56

Edgewise Therapeutics, Inc. reported an amended insider transaction for its CMO, Joanne M. Donovan.

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. reported an amended insider transaction for its CMO, Joanne M. Donovan. She received a grant of 65,000 stock options to purchase common stock at an exercise price of $43.56 per share, expiring on August 12, 2036. The company states this amendment corrects a clerical error in the originally reported exercise price. The options vest in equal monthly installments over four years starting on September 12, 2026, contingent on her continued service.

Insider Trade Summary

Grant/Award: 65,000 shares

Grant/Award 1 txn

Insider Donovan Joanne M.

Role CMO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	65,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 65,000 contracts (Direct)

Footnotes (1)

1. F1. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

Key Figures

Options Granted: 65,000 shares Exercise Price: $43.56 per share Expiration Date: 2036-08-12 +3 more

6 metrics

Options Granted 65,000 shares Stock Option (Right to Buy) granted to CMO on 2026-08-12

Exercise Price $43.56 per share Corrected exercise price reflecting fair market value on grant date

Expiration Date 2036-08-12 Option expiration for 65,000-share grant

Underlying Shares 65,000 shares Underlying common stock tied to the stock option grant

Vesting Rate 1/48 per month 1/48th of option shares vest monthly starting 2026-09-12

Vesting Start Date 2026-09-12 First vesting date contingent on continued service

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"The correct exercise price is $43.56, which reflects the fair market value"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"1/48th of the shares subject to the option vest each month"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-08-12"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Edgewise Therapeutics (EWTX) report in this Form 4/A?

Edgewise Therapeutics reported a grant of 65,000 stock options to CMO Joanne M. Donovan. These options allow her to purchase common stock at a fixed exercise price, subject to long-term vesting and continued service.

What is the corrected exercise price of the EWTX stock options granted to Joanne M. Donovan?

The corrected exercise price is $43.56 per share. The amendment states this price reflects the fair market value of Edgewise Therapeutics common stock on the grant date and corrects a prior clerical reporting error.

How many Edgewise Therapeutics (EWTX) options does Joanne M. Donovan hold after this grant?

Following this transaction, Joanne M. Donovan holds 65,000 stock options related to this grant. These options are reported as directly owned and are subject to a multi-year vesting schedule starting in 2026.

When do Joanne M. Donovan’s EWTX stock options start vesting and over what period?

Vesting begins on September 12, 2026. According to the disclosure, 1/48th of the option shares vest each month thereafter, contingent on her continuing as a service provider through each vesting date.

When do the stock options granted to the EWTX CMO expire?

The reported stock options expire on August 12, 2036. After this expiration date, any unexercised options from this grant would no longer be exercisable under the terms described.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 06:41 PM Accepted by SEC EDGAR 08/17/2026 - 06:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donovan Joanne M.

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
08/14/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$43.56	08/12/2026		A		65,000		(1)	08/12/2036	Common Stock	65,000	$0.00	65,000	D

Explanation of Responses:

1. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

Remarks:

This amendment corrects the exercise price of the reported option grant, which was reported as $0.00 due to a clerical/administrative error. The correct exercise price is $43.56, which reflects the fair market value of the underlying security on the date of grant.

	John R. Moore Attorney-in-Fact for Donovan Joanne M.	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)